Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Current Options in the Diagnosis and Treatment of Monkeypox

Current Options in the Diagnosis and Treatment of Monkeypox Purpose of ReviewThis review summarizes the current options for human monkeypox virus diagnostic testing, vaccination, and treatment.Recent FindingsInformation on non-lesion monkeypox virus diagnostic testing is limited to small studies with unclear sensitivities and specificities. Early data on the JYNNEOS vaccine has shown a lower incidence of monkeypox infection among vaccinated individuals. Drug options for human monkeypox, which include tecovirimat, cidofovir, brincidofovir, and vaccinia immune globulin intravenous, are limited without an FDA-approved medication and data on drug efficacy pending.SummaryData on non-lesion-based tests for human monkeypox infection, though limited, seems promising for certain clinical manifestations and to potentially screen asymptomatic patients if there is conclusive evidence of asymptomatic transmission. Vaccination with JYNNEOS appears effective in the prevention of monkeypox infection in early data. Of the limited medications available for monkeypox, tecovirimat’s safety profile appears to be the best with data suggestive of efficacy though further conclusive evidence from clinical trials is lacking. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Fungal Infection Reports Springer Journals

Current Options in the Diagnosis and Treatment of Monkeypox

Torres, Heidi M.
Current Fungal Infection Reports , Volume 16 (4) – Dec 1, 2022
Download PDF
6 pages

Loading next page...
 
/lp/springer-journals/current-options-in-the-diagnosis-and-treatment-of-monkeypox-EUrtqRFLcQ
Publisher
Springer Journals
Copyright
Copyright © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
1936-3761
eISSN
1936-377X
DOI
10.1007/s12281-022-00448-8
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewThis review summarizes the current options for human monkeypox virus diagnostic testing, vaccination, and treatment.Recent FindingsInformation on non-lesion monkeypox virus diagnostic testing is limited to small studies with unclear sensitivities and specificities. Early data on the JYNNEOS vaccine has shown a lower incidence of monkeypox infection among vaccinated individuals. Drug options for human monkeypox, which include tecovirimat, cidofovir, brincidofovir, and vaccinia immune globulin intravenous, are limited without an FDA-approved medication and data on drug efficacy pending.SummaryData on non-lesion-based tests for human monkeypox infection, though limited, seems promising for certain clinical manifestations and to potentially screen asymptomatic patients if there is conclusive evidence of asymptomatic transmission. Vaccination with JYNNEOS appears effective in the prevention of monkeypox infection in early data. Of the limited medications available for monkeypox, tecovirimat’s safety profile appears to be the best with data suggestive of efficacy though further conclusive evidence from clinical trials is lacking.

Journal

Current Fungal Infection Reports – Springer Journals

Published: Dec 1, 2022

Keywords: Human monkeypox virus; Monkeypox outbreak; Monkeypox PCR; Tecovirimat; Brincidofovir; Cidofovir

References

  • Monkeypox: A focused narrative review for emergency medicine clinicians
    Long, B; Koyfman, A; Gottlieb, M; Liang, SY; Carius, BM; Chavez, S; Brady, WJ
  • Evaluation of the GeneXpert for human monkeypox diagnosis
    Li, D; Wilkins, K; McCollum, AM; Osadebe, L; Kabamba, J; Ngueteet, B
  • Clinical features and management of human monkeypox: a retrospective observational study in the UK
    Adler, H; Gould, S; Hine, P; Snell, LB; Wong, W; Houlihan, CF
  • Epidemiological, clinical and virological characteristics of four cases of monkeypox support transmission through sexual contact, Italy, May 2022
    Antinori, A; Mazzotta, V; Vita, S; Carletti, F; Tacconi, D; Lapini, LE
  • Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium
    De Baetselier, I; Van Dijck, C; Kenyon, C; Coppens, J; Michiels, J; De Block, T
  • Compassionate use of tecovirimat for the treatment of monkeypox infection
    Desai, A; Thompson, G; Neumeister, S; Arutyunova, A; Trigg, K; Cohen, S
  • Clinical use of tecovirimat (Tpoxx) for treatment of monkeypox under an investigational new drug protocol — United States, May–August 2022
    O’Laughlin, K; Tobolowsky, F; Elmor, R; Overton, R; O’Connor, SM; Damon, IK
  • Antivirals with activity against monkeypox: a clinically oriented review
    Siegrist, E; Sassine, J
  • Strategies adopted by gay, bisexual, and other men who have sex with men to prevent monkeypox virus transmission — United States, August 2022
    Delaney, K; Sanchez, T; Hannah, M